who yearn to be gods.
You might want to start by reading https://www.bucksafa11.org/2019/08/26/you-might-not-think-slaverys-so-bad-now/
before moving on to
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560170/
January 14 2013
As the worldwide human antibody gene transfer experiments continue on, what they who are behind it fail to share with the public in their coercive propaganda programming is their decades old documented scientific history; a history that openly acknowledges bypassing the natural immune system results in complexities that turn their planned implanted nano-control knob into a long term T-1000 type detour.
After learning that the results of two studies were reason enough for modern science poohbahs to abandon their previously established and rigorously defended method of ‘harnessing the natural immune system’, it occurred to me documentation of the results of efforts of the new vaxx technocrats might be a helpful clarification for the purposely misguided, thus enabling parity for the UNdereducated public who are embracing the built in mediocrity of the ‘go along to get along’ philosophy the https://lasd.org/operation-homebound army of the mundane enforces; that is, a parity with the mask-less who had no problem detecting the grievous opprobrium of the weightless political stench early on in this power grab.
Aug 01, 2001
https://www.cell.com/action/showPdf?pii=S1525-0016%2801%2990435-6
Gene replacement therapy represents an interesting new approach for the treatment of cystic fibrosis (CF) lung disease. Basic research suggests that CF gene therapy is feasible, but major technological
challenges must be addressed before clinical applications are likely to succeed…
Oct 3, 2002
https://www.nature.com/articles/3301791.pdf
Conclusion
Although topical gene transfer to the airways for CF gene therapy is more challenging than originally thought, significant progress has been made in pre-clinical research over the last 2 years to overcome some of the hurdles.
Most importantly, the identification of more effective viral and non-viral gene transfer agents for airway gene delivery, development of new delivery routes and most recently alternative strategies are keeping the development of CF gene therapy well on track.
Sept 29 2004
https://www.nature.com/articles/3302368.pdf
Over the last decade, it became apparent that gene transfer to the AECs is difficult. This is perhaps unsurprising, given the lung has evolved to keep foreign particles out. The major obstacle for most viral GTAs is the effective immune surveillance mechanisms in the
lung, which prohibit repeat administration. Many strategies
to overcome this problem have already been
explored, but have not yet been successful. In our view,
this may be a difficult hurdle to overcome.
Non-viral gene transfer has traditionally been inefficient, but recently developed nanoparticles and ligand-targeting appear
to be overcoming this problem. Importantly, physical
delivery methods to increase non-viral gene transfer are
currently being assessed in the lung. Although gene
therapy for CF is not yet a clinical reality, the many
innovative strategies currently being assessed should
lead to efficient and repeatable airway gene transfer
within the next few years.
April 1 2014
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3996976/
James W Wilson :
At the turn of the century, the field of gene therapy saw a significant erosion of support for a variety of reasons (Wilson, 2009). Despite extensive clinical trial activity, the field had no clear demonstration of clinical success. My assessment was that available vector technology was not suitable for most of the clinical applications that were contemplated. I approached Tachi Yamada, who at the time was chief scientific officer of SmithKlineBeecham (SB), for advice about the current state of the field and what I could do to move it forward. Tachi was the chair of my department at Michigan and a very important mentor. He encouraged me to “go back to the bench” and focus on creating better vectors and offered to have SB help support this effort through a sizable sponsored research agreement with Penn. We had the financial support—we now needed a plan!
March 9 2015
https://www.nytimes.com/2015/03/10/health/protection-without-a-vaccine.html
It’s not a vaccine.
Aug 2016
Biogen and UPenn join forces to commercialize gene therapies
January 31 2018
The warning comes amidst a scramble by three companies—Sarepta Therapeutics, Pfizer, and Solid Biosciences—to be the first to use the technique to cure muscular dystrophy. That disease strikes young boys, destroys their muscles, and kills them by their 20s.
May 24 2019
Sept 12 2019
https://cen.acs.org/business/The-redemption-of-James-Wilson-gene-therapy-pioneer/97/i36
Squinto was astounded. “He runs his gene therapy center like you’d run a very efficient company,” he thought. With Wilson’s infrastructure and decades of know-how, any spin-off company financed by Squinto’s firm could hit the ground running. “It’s all here,” he told Wilson. “And I’m willing to pay for it.”
Over the next few months, the duo negotiated an intimate arrangement: they would form a new company, and Wilson’s lab at Penn would function as its R&D arm…
April 17 2020
…The importance of the cystic fibrosis gene discovery went far beyond a single illness. It helped build the case for the $3 billion project to sequence the entire human genome, which would alter understanding of human biology and shed light on rare and common diseases.
But the story of cystic fibrosis has been illustrative in a way that no one could have anticipated back then. In the early days of human genetics, the path seemed straightforward: Find the gene, fix the gene and repeat for other diseases. The cystic fibrosis journey, from an exuberant moment of insight to a major success, would take 30 years of persistent, methodical work: a feat of science, business, fundraising and patience that has become a model for other diseases.
2015 Jul 22
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632204/
Safety monitoring in the Vaccine Adverse Event Reporting System
Abstract